Skip to search formSkip to main contentSkip to account menu

Fasidotrilat

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Vasopeptidase inhibitors (VPI) are a new promising class of drugs, that simultaneously inhibit Angiotensin - Converting Enzyme… 
Review
2003
Review
2003
Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of… 
1998
1998
The acute diuretic and natriuretic effects of fasidotrilat, a mixed inhibitor of neutral endopeptidase (NEP) and angiotensin I…